Takeaway
Nitric Oxide (NO) and glutamate may be potential biomarkers for disease activity in patients with multiple sclerosis (MS).
Why this matters
Although there are several diagnostic tests, MS remains a clinical diagnosis based on supportive paraclinical evidence.
However, glutamate and NO may be promising as biomarkers for predicting the occurrence or relapse in a MS patient and be objective clues for the diagnosis of a relapse, especially when pseudo-relapse is suspected.